RESPOND study is actively enrolling, with baseline characteristics reporting infants and toddlers have residual unmet medical needs in multiple areas after gene therapy; SPINRAZA treatment following gene
WESTON (dpa-AFX) - Biogen Inc. (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) said Biogen exercised its option to obtain from Ionis a worldwide, royalty-bearing license to develop and commercialize